Arguably, rapid detection of mutated genes using IHC allows attending clinicians to rationally select targeted therapies for neoplasms known to harbor HRAS, NRAS or KRAS p.Q61R mutations including ameloblastoma, melanoma, colorectal, urothelial and thyroid cancers, among others (35). Here, HRAS is linked to ameloblastoma.